

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**



03-18-04

PC019090B

PC019090B/AG0136-02
REQUEST FOR CORRECTED FILING RECEIPT

Certificate of Mailing (37 C.F.R. §1.10):

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail (#EV 291841808 US) in an envelope addressed to:
Mail Stop: Application Number,
Commissioner for Patents,
PO Box 1450, Alexandria, VA 22313-1450
on this 16th day of March 2004.

s/ Pamela Hollander
Pamela Hollander

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:
David John KUCERA et al.

Serial No.: 10/728,602

Filed: December 4, 2003

For: HIV PROTEASE INHIBITORS,
COMPOSITIONS CONTAINING THE SAME,
THEIR PHARMACEUTICAL USES AND
MATERIALS FOR THEIR SYNTHESIS

Group Art Unit: 1626

Examiner: Not Yet Assigned

REQUEST FOR CORRECTED FILING RECEIPT

Mail Stop Application Number
Commissioner For Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Please make the following corrections to the filing receipt and kindly generate another Filing Receipt incorporating the requested corrections:

--Please change the FILING OR 371(c) DATE to 12/04/2003--

The above-identified application was deposited in Express Mail with the United States Postal Service on December 4, 2003, as evidenced by an enclosed copy of the official receipt bearing a December 4, 2003 date stamp. In addition, a copy of the Transmittal Letter is enclosed in which Pamela Hollander certifies that the papers were deposited in Express Mail with the United States Postal Service on December 4, 2003.

As such, Applicants believe they are entitled to a filing date for the above-identified application of **December 4, 2003**.



No fee is believed to be due at this time. If the applicant is in error, please charge all fees related to this filing to Deposit Account No. 500329.

Respectfully submitted,

Date: March 16, 2004


Jeffrey M. Tidwell
Attorney For Applicants
Registration No. 47,995

Agouron Pharmaceuticals, Inc./A Pfizer Company
Patent Department
10777 Science Center Drive
San Diego, California 92121
Phone: (858) 638-3877
Fax: (858) 678-8233



Filed in the U.S. Patent and Trademark Office via Express Mail No. EV 34107997 US

Attorney Docket No.: PC19090B / AG0136-02

U.S. Patent Application Serial No. To be Assigned Filed: To be Assigned Confirmation # To be Assigned

In Re Application of: David John KUCERA

Title: HIV Protease Inhibitors, Compositions Containing the Same, Their Pharmaceutical Uses and Materials for their Synthesis

Please date stamp and return this postage-prepaid card to applicant to show receipt of the following enclosures:

Transmittal Letter	1 page;
Application Data Sheet	2 pages;
Utility Patent Application Transmittal	1 page;
Specification	228 pages;
Claims	6 pages;
Abstract	1 page; and
Fee Transmittal	1 page (+ duplicate).

Date: December 4, 2003

Responsible Atty: Jeffrey H. Tidwell

Filed in the U.S. Patent and Trademark Office via Express Mail No. EV 34107997 US

Attorney Docket No.: PC19090B / AG0136-02

U.S. Patent Application Serial No. To be Assigned Filed: To be Assigned Confirmation # To be Assigned

In Re Application of: David John KUCERA

Title: HIV Protease Inhibitors, Compositions Containing the Same, Their Pharmaceutical Uses and Materials for their Synthesis

Please date stamp and return this postage-prepaid card to applicant to show receipt of the following enclosures:

Transmittal Letter	1 page;
Application Data Sheet	2 pages;
Utility Patent Application Transmittal	1 page;
Specification	228 pages;
Claims	6 pages;
Abstract	1 page; and
Fee Transmittal	1 page (+ duplicate).

RECEIVED

DEC 18 2003

Date: December 4, 2003

Responsible Atty: Jeffrey H. Tidwell

LA JOLLA PATENT DEPT

315342 U.S. PTO
10/728602



120503



Certificate of Mailing (37 C.F.R. §1.10):

I hereby certify that this correspondence is being deposited with the United States Postal Service as **Express Mail (EV 34107997 US)** in an envelope addressed to: Mail Stop: Patent Applications Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450 on this 4th day of December 2003.

s/ Pamela Hollander
Pamela Hollander, M.A.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:
David John KUCERA, et al.

Serial No.: To be Assigned

Filed: Herewith

For: HIV Protease Inhibitors, Compositions
Containing the Same, Their Pharmaceutical
Uses and Materials for their Synthesis

Group Art Unit: To be Assigned

Examiner: To be Assigned

Mail Stop: Patent Applications
Honorable Commissioner For Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Transmitted herewith are the following documents:

Return Receipt Postcard
Application Data Sheet
Utility Patent Application Transmittal
Specification
Claims
Abstract
Fee Transmittal


1 page;
2 pages;
1 page;
228 pages;
6 pages;
1 page; and
1 page (+ duplicate).

Respectfully submitted,

Date: December 4, 2003

Jeffrey H. Tidwell
Jeffrey H. Tidwell
Attorney For Applicants
Registration No. 47,995

Agouron Pharmaceuticals, Inc./A Pfizer Company
Patent Department
10777 Science Center Drive
San Diego, California 92121
Phone: (858) 638-3877
Fax: (858) 678-8233

**UTILITY
PATENT APPLICATION
TRANSMITTAL**

Attorney Docket No.

PC019090B / AG 0136 - 02

First Inventor

David John Kucera

Title

HIV Protease Inhibitors, Compositions
Containing the Same, Their
Pharmaceutical Uses, Material for Their
Synthesis

Express Mail Label No.

EV 341079927 US

(Only for new nonapplications under 37C.F.R. §1.53(b))

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

ADDRESS TO:

Mail Stop Patent Applications
Commissioner for Patents
Box 1450
Alexandria, VA 22313-1450

1. ☒ Fee Transmittal Form (e.g., PTO/SB/17)
(Submit an original, and a duplicate for fee processing)

2. ☐ Applicant claims small entity status
See 37 CFR 1.27

3. ☒ Specification [Total Pages **235**]
(preferred arrangement set forth below)
- Descriptive title of the Invention
 - Cross References to Related Applications
 - Statement Regarding Fed sponsored R&D
 - Reference to sequence listing, a table, or a computer program listing appendix
 - Background of the Invention
 - Brief Summary of the Invention
 - Brief Description of the Drawings (if filed)
 - Detailed Description
 - Claim(s)
 - Abstract of the Disclosure

4. ☐ Drawing(s) (35 U.S.C. 113) [Total sheets _____]

5. ☐ Oath or Declaration [Total pages _____]
- a. ☐ Newly executed (original or copy)
- b. ☐ Copy from a prior application (37 CFR §1.63(d))
(for continuation/divisional with Box 18 completed)
- i. ☐ **DELETION OF INVENTOR(S)**
Signed statement attached deleting inventor(s)
named in the prior application, see 37 CFR
1.63(d)(2) and 1.33(b).

6. ☒ Application Data Sheet. See 37 CFR 1.76

7. ☐ CD-ROM or CD-R in duplicate, large table or
computer Program (Appendix)
8. Nucleotide and/or Amino Acid Sequence Submission
(if applicable, all necessary)

- a. ☐ Computer Readable Copy (CRF)
- b. Specification Sequence Listing on:
- i. ☐ CD-ROM or CD-R (2 copies)
- ii. ☐ Paper
- c. ☐ Statement verifying identity of above copies

ACCOMPANYING APPLICATION PARTS

9. ☐ Assignment Papers (cover sheet & document(s))
10. ☐ 37 CFR 3.73(b) Statement ☐ Power of Attorney
(when there is an assignee)
11. ☐ English Translation Document (if applicable)
12. ☐ Information Disclosure ☐ Copies of IDS
Statement (IDS)/PTO-1449 Citations
13. ☐ Preliminary Amendment
14. ☒ Return Receipt Postcard (MPEP 503)
(Should be specifically itemized)
15. ☐ Certified Copy of Priority Document(s)
(if foreign priority is claimed)
16. ☐ Nonpublication Request under 35 U.S.C. 122
(b)(2)(B)(i). Applicant must attach form PTO/SB/35
or its equivalent.
17. ☐ Other:

18. If a **CONTINUING APPLICATION**, check appropriate box, and supply the requisite information below and in a preliminary amendment,
or in an Application Data Sheet under 37CFR 1.76.

☐ Continuation ☐ Divisional ☒ Continuation-in-part (CIP) of prior application No. 10/166,957

Prior application information: Examiner Group/Art Unit: 1625

For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts

19. CORRESPONDENCE ADDRESS☒ Customer Number

28940

or ☐ Correspondence address below

Name

Address

City

State

Zip Code

Country

Telephone

Fax

NAME (Print/type)

Jeffery H. Tidwell

Registration No. (Attorney/Agent)

47,995

Signature

Date

December 4, 2003

